首页 > 市场调查报告书 > 製药

癌症生物标记

市场调查报告书

商品编码

1461319

癌症生物标记市场，按生物标记类型，按癌症类型，按分析技术，按最终用户，按地理位置

Cancer Biomarkers Market, By Biomarker Type, By Cancer Type, By Profiling Technology, By End User, By Geography

出版日期: 2024年03月22日 | 出版商:

Coherent Market Insights | 英文 156 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球癌症生物标记市场价值为256亿美元，预计到2031年将达到590.1亿美元，2024年至2031年年复合成长率（CAGR）为12.7%。

报告范围		报告详情
基准年：	2023年	2023/2024 年市场规模：	256亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测期间 2023/2024 至 2030/2031 年复合成长率：	12.70%	2030/2031 价值预测：	590.1 亿美元

癌症生物标记市场占有率 (%)（按地区），2024 年

癌症生物标记是在血液、组织或其他体液中发现的生物分子，是正常或异常过程、状况或疾病的标誌。这些可用于检测和监测癌症或癌症进展。近年来，癌症生物标记引起了全球公共和私人组织的极大关注，因为它们提供了诊断、分期和追踪癌症的微创方法。它们的使用也使肿瘤学家能够根据个别患者的癌症概况进行个人化治疗。基因分析和高通量技术的进步释放了生物标记的潜力，可以更准确地预测治疗反应和疾病进展。这对于改善全球癌症护理具有广阔的前景。

市场动态：

全球癌症生物标记市场的成长是由全球癌症盛行率上升、精准医疗和伴随诊断的日益普及以及生物标记在药物开发和审批中的使用不断增加所推动的。然而，与生物标记发现、验证和商业化相关的高成本构成了挑战。此外，技术限制和缺乏报销限制了市场的成长。市场见证了癌症人口众多且医疗支出不断增长的新兴经济体带来的利润丰厚的机会。进一步的机会在于透过持续的研究工作发现新的生物标记物，特别是针对难以治疗的癌症。

研究的主要特点：

该报告对全球癌症生物标记市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数描述了全球癌症生物标记市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球癌症生物标誌物市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球癌症生物标记市场的各种策略矩阵轻鬆做出决策。

介绍
北美洲
我们
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地区
欧洲
英国
德国
义大利
法国
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
东协
澳洲
韩国
亚太地区其他地区
中东
海湾合作委员会
以色列
中东其他地区
非洲
北非
中非
南非

第 10 章：竞争格局

bioMerieux, Inc.
INOVIQ
Bio-Rad Laboratories, Inc.
Abbott
Becton, Dickinson and Company
Merck KGaA
QIAGEN
Thermo Fisher Scientific Inc.
CENTOGENE N.V.
PerkinElmer Inc.
Siemens Healthineers
F. Hoffmann-la Roche Ltd
Agilent Technologies, Inc
Invitae Corporation
Myriad Genetics
Guardant Health
Illumina
FOUNDATION MEDICINE, INC.

第 11 章：分析师观点

命运之轮
分析师观点
连贯的机会图

第 12 章：参考文献与研究方法

参考
研究方法论

简介目录

Product Code: CMI175

Global cancer biomarkers market is estimated to be valued at USD 25.60 Bn in 2024 and is expected to reach USD 59.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 25.60 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	12.70%	2030/2031 Value Projection:	US$ 59.01 Bn

Cancer Biomarkers Market Share (%), By Region, 2024

Cancer biomarkers are biological molecules found in blood, tissues or other body fluids that are sign of a normal or abnormal process, or of a condition or disease. These can be used to detect and monitor cancer or cancer progression. In recent years, cancer biomarkers have gained significant attention from both global public and private organizations as these present minimally invasive ways to diagnose, stage and track cancer. Their use also enables oncologists to personalize treatments based on individual patient's cancer profiles. Advancements in genetic profiling and high-throughput technologies have unlocked the potential of biomarkers that can predict treatment responses and disease progression more accurately. This has promising implications for improving cancer care globally.

Market Dynamics:

Global cancer biomarkers market growth is driven by rising cancer prevalence worldwide, increasing popularity of precision medicine and companion diagnostics, and growing use of biomarkers in drug development as well as approvals. However, high costs associated with biomarker discovery, validation, and commercialization pose a challenge. Moreover, technical limitations and lack of reimbursements restrain the market growth. The market witnesses lucrative opportunities from emerging economies with large cancer populations and growing health expenditures. Further opportunities lie in discovery of novel biomarkers especially for hard-to-treat cancers through ongoing research efforts.

Key Features of the Study:

This report provides in-depth analysis of the global cancer biomarkers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global cancer biomarkers market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study includes bioMerieux Inc., INOVIQ, Bio-Rad Laboratories Inc., Abbott, Becton Dickinson and Company, Merck KGaA, QIAGEN N.V., Thermo Fisher Scientific Inc., CENTOGENE N.V., PerkinElmer Inc., Siemens Healthineers, F. Hoffmann-la Roche Ltd, Agilent Technologies, Inc, Invitae Corporation, Myriad Genetics, Guardant Health, Illumina, and FOUNDATION MEDICINE, INC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global cancer biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer biomarkers market

Detailed Segmentation-

Biomarker Type:
- CA 125
- HER2
- EGFR
- CD20
- BRAF
- Calcitonin
- Others
Cancer Type:
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Kidney Cancer
- Liver Cancer
- Head & neck Cancer
- Non-small Cell Lung Cancer
- Other Cancers
Profiling Technology:
- OMICS Technology
- Imaging Technology
- Immunoassays
- Cytogenetics
- Others
End User:
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Academic Research Institutes
- Others
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- bioMerieux Inc.
- INOVIQ
- Bio-Rad Laboratories Inc.
- Abbott
- Becton Dickinson and Company
- Merck KgaA
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
- CENTOGENE N.V.
- PerkinElmer Inc.
- Siemens Healthineers
- Hoffmann-la Roche Ltd
- Agilent Technologies, Inc
- Invitae Corporation
- Myriad Genetics
- Guardant Health
- Illumina
- FOUNDATION MEDICINE, INC.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Biomarker Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By Profiling Technology
- Market Snapshot, By End User
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Recent Developments
Acquisitions and Partnerships Scenario
Technology Overview
Regulatory Scenario
PEST Analysis

4. Global Cancer Biomarkers Market- Impact of Coronavirus (COVID-19) Pandemic

Overall Impact
Impact on Supply and Demand
COVID-19 Impact on the market

5. Global Cancer Biomarkers Market, By Biomarker Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
CA 125
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
HER2
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
EGFR
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
CD20
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
BRAF
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Calcitonin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Cancer Biomarkers Market, By Cancer Type, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Breast Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Prostate Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Kidney Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Liver Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Head & neck Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Non-small Cell Lung Cancer
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Other Cancers
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Cancer Biomarkers Market, By End User, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
OMICS Technology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Imaging Technology
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Immunoassays
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Cytogenetics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Cancer Biomarkers Market, By End User, 2019 - 2031, (USD BN)

Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospitals
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Specialty Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Diagnostic Laboratories
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Academic & Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

9. Global Cancer Biomarkers Market, By Region, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2020-2031
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Biomarker Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Profiling Technology, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
GCC
Israel
Rest of Middle East
Africa
North Africa
Central Africa
South Africa

10. Competitive Landscape

bioMerieux, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
INOVIQ
Bio-Rad Laboratories, Inc.
Abbott
Becton, Dickinson and Company
Merck KGaA
QIAGEN
Thermo Fisher Scientific Inc.
CENTOGENE N.V.
PerkinElmer Inc.
Siemens Healthineers
F. Hoffmann-la Roche Ltd
Agilent Technologies, Inc
Invitae Corporation
Myriad Genetics
Guardant Health
Illumina
FOUNDATION MEDICINE, INC.